Mucin Binding Lectin Imaging Agents for Colonic Polyp Imaging
Posted Feb 29 2008 4:00pm
Description of Invention: Available for licensing and commercial development is an imaging agent specific for colonic polyps that overexpress glycoprotein alpha-L-fucose containing mucins. Colon cancer is the second leading cause of cancer related deaths in the United States. The legume protein Ulex europaeus agglutinin I (UEA-1) has shown high specificity to alpha-L-fucose glycoproteins. Colonic mucosal neoplasia and/or polyps with high surface expression of alpha-L-fucosyl terminal residues can be specifically targeted with UEA-1 contrast agents. In one example, a computer tomography (CT) agent made from Iodine-127 (127I) labeled UEA-1 (I-UEA-1) and encapsulated into polymeric liposome nanoparticles was used to image murine colonic polyps. Ideally, the inventors envision a contrast agent that can be administered orally (e.g., liquid or pill form) and that would eliminate a patient’s need to drink harsh enema/contrast solutions prior to CT imaging.